126 related articles for article (PubMed ID: 21719463)
1. Elucidation of the contribution of active site and exosite interactions to affinity and specificity of peptidylic serine protease inhibitors using non-natural arginine analogs.
Hosseini M; Jiang L; Sørensen HP; Jensen JK; Christensen A; Fogh S; Yuan C; Andersen LM; Huang M; Andreasen PA; Jensen KJ
Mol Pharmacol; 2011 Oct; 80(4):585-97. PubMed ID: 21719463
[TBL] [Abstract][Full Text] [Related]
2. A cyclic peptidylic inhibitor of murine urokinase-type plasminogen activator: changing species specificity by substitution of a single residue.
Andersen LM; Wind T; Hansen HD; Andreasen PA
Biochem J; 2008 Jun; 412(3):447-57. PubMed ID: 18318660
[TBL] [Abstract][Full Text] [Related]
3. The binding mechanism of a peptidic cyclic serine protease inhibitor.
Jiang L; Svane AS; Sørensen HP; Jensen JK; Hosseini M; Chen Z; Weydert C; Nielsen JT; Christensen A; Yuan C; Jensen KJ; Nielsen NC; Malmendal A; Huang M; Andreasen PA
J Mol Biol; 2011 Sep; 412(2):235-50. PubMed ID: 21802428
[TBL] [Abstract][Full Text] [Related]
4. A cyclic peptidic serine protease inhibitor: increasing affinity by increasing peptide flexibility.
Zhao B; Xu P; Jiang L; Paaske B; Kromann-Hansen T; Jensen JK; Sørensen HP; Liu Z; Nielsen JT; Christensen A; Hosseini M; Sørensen KK; Nielsen NC; Jensen KJ; Huang M; Andreasen PA
PLoS One; 2014; 9(12):e115872. PubMed ID: 25545505
[TBL] [Abstract][Full Text] [Related]
5. A urokinase-type plasminogen activator-inhibiting cyclic peptide with an unusual P2 residue and an extended protease binding surface demonstrates new modalities for enzyme inhibition.
Hansen M; Wind T; Blouse GE; Christensen A; Petersen HH; Kjelgaard S; Mathiasen L; Holtet TL; Andreasen PA
J Biol Chem; 2005 Nov; 280(46):38424-37. PubMed ID: 16141208
[TBL] [Abstract][Full Text] [Related]
6. Distinctive binding modes and inhibitory mechanisms of two peptidic inhibitors of urokinase-type plasminogen activator with isomeric P1 residues.
Jiang L; Zhao B; Xu P; Sørensen HP; Jensen JK; Christensen A; Hosseini M; Nielsen NC; Jensen KJ; Andreasen PA; Huang M
Int J Biochem Cell Biol; 2015 May; 62():88-92. PubMed ID: 25744057
[TBL] [Abstract][Full Text] [Related]
7. Selection of High-Affinity Peptidic Serine Protease Inhibitors with Increased Binding Entropy from a Back-Flip Library of Peptide-Protease Fusions.
Sørensen HP; Xu P; Jiang L; Kromann-Hansen T; Jensen KJ; Huang M; Andreasen PA
J Mol Biol; 2015 Sep; 427(19):3110-22. PubMed ID: 26281711
[TBL] [Abstract][Full Text] [Related]
8. Interconversion of active and inactive conformations of urokinase-type plasminogen activator.
Liu Z; Kromann-Hansen T; Lund IK; Hosseini M; Jensen KJ; Høyer-Hansen G; Andreasen PA; Sørensen HP
Biochemistry; 2012 Oct; 51(39):7804-11. PubMed ID: 22950516
[TBL] [Abstract][Full Text] [Related]
9. Contribution of peptide bonds to inhibitor-protease binding: crystal structures of the turkey ovomucoid third domain backbone variants OMTKY3-Pro18I and OMTKY3-psi[COO]-Leu18I in complex with Streptomyces griseus proteinase B (SGPB) and the structure of the free inhibitor, OMTKY-3-psi[CH2NH2+]-Asp19I.
Bateman KS; Huang K; Anderson S; Lu W; Qasim MA; Laskowski M; James MN
J Mol Biol; 2001 Jan; 305(4):839-49. PubMed ID: 11162096
[TBL] [Abstract][Full Text] [Related]
10. Insight to the residue in P2 position prevents the peptide inhibitor from being hydrolyzed by serine proteases.
Xue G; Xie X; Zhou Y; Yuan C; Huang M; Jiang L
Biosci Biotechnol Biochem; 2020 Jun; 84(6):1153-1159. PubMed ID: 32019421
[TBL] [Abstract][Full Text] [Related]
11. Structural basis of specificity of a peptidyl urokinase inhibitor, upain-1.
Zhao G; Yuan C; Wind T; Huang Z; Andreasen PA; Huang M
J Struct Biol; 2007 Oct; 160(1):1-10. PubMed ID: 17692534
[TBL] [Abstract][Full Text] [Related]
12. Bicyclic peptide inhibitor of urokinase-type plasminogen activator: mode of action.
Roodbeen R; Paaske B; Jiang L; Jensen JK; Christensen A; Nielsen JT; Huang M; Mulder FA; Nielsen NC; Andreasen PA; Jensen KJ
Chembiochem; 2013 Nov; 14(16):2179-88. PubMed ID: 24115455
[TBL] [Abstract][Full Text] [Related]
13. Design of P1' and P3' residues of trivalent thrombin inhibitors and their crystal structures.
Slon-Usakiewicz JJ; Sivaraman J; Li Y; Cygler M; Konishi Y
Biochemistry; 2000 Mar; 39(9):2384-91. PubMed ID: 10694407
[TBL] [Abstract][Full Text] [Related]
14. A novel serine protease inhibition motif involving a multi-centered short hydrogen bonding network at the active site.
Katz BA; Elrod K; Luong C; Rice MJ; Mackman RL; Sprengeler PA; Spencer J; Hataye J; Janc J; Link J; Litvak J; Rai R; Rice K; Sideris S; Verner E; Young W
J Mol Biol; 2001 Apr; 307(5):1451-86. PubMed ID: 11292354
[TBL] [Abstract][Full Text] [Related]
15. Binding of amino acid side-chains to S1 cavities of serine proteinases.
Lu W; Apostol I; Qasim MA; Warne N; Wynn R; Zhang WL; Anderson S; Chiang YW; Ogin E; Rothberg I; Ryan K; Laskowski M
J Mol Biol; 1997 Feb; 266(2):441-61. PubMed ID: 9047374
[TBL] [Abstract][Full Text] [Related]
16. Cleavage of peptidic inhibitors by target protease is caused by peptide conformational transition.
Jiang L; Oldenburg E; Kromann-Hansen T; Xu P; Jensen JK; Andreasen PA; Huang M
Biochim Biophys Acta Gen Subj; 2018 Sep; 1862(9):2017-2023. PubMed ID: 29959058
[TBL] [Abstract][Full Text] [Related]
17. Insights into the serine protease mechanism based on structural observations of the conversion of a peptidyl serine protease inhibitor to a substrate.
Jiang L; Andersen LM; Andreasen PA; Chen L; Huang M
Biochim Biophys Acta; 2016 Mar; 1860(3):599-606. PubMed ID: 26691138
[TBL] [Abstract][Full Text] [Related]
18. Distal hinge of plasminogen activator inhibitor-1 involves its latency transition and specificities toward serine proteases.
Wang Q; Shaltiel S
BMC Biochem; 2003 Jul; 4():5. PubMed ID: 12848892
[TBL] [Abstract][Full Text] [Related]
19. Kinetics of factor Xa inhibition by recombinant tick anticoagulant peptide: both active site and exosite interactions are required for a slow- and tight-binding inhibition mechanism.
Rezaie AR
Biochemistry; 2004 Mar; 43(12):3368-75. PubMed ID: 15035608
[TBL] [Abstract][Full Text] [Related]
20. Molecular basis of specific inhibition of urokinase plasminogen activator by amiloride.
Jankun J; Skrzypczak-Jankun E
Cancer Biochem Biophys; 1999 Jul; 17(1-2):109-23. PubMed ID: 10738907
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]